Type 2 Diabetes Clinical Trial
Official title:
Effects of Cognitive Behavioral Therapy for Insomnia in Type 2 Diabetes Mellitus: A Randomized Controlled Trial
NCT number | NCT06202742 |
Other study ID # | MURA2023/873 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 8, 2024 |
Est. completion date | June 2025 |
This study will explore the effects of cognitive behavioral therapy for insomnia (CBTI) compare to health educations in patients with type 2 diabetes (T2DM) with insomnia symptoms.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | June 2025 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 30 Years to 65 Years |
Eligibility | Inclusion Criteria: - Type 2 diabetes mellitus age 30 to 65 years old - Hemoglobin A1C = 6.5 but = 10 % - Have poor sleep quality as assessed by Insomnia Severity Index = 15 - Receive the same hypoglycemic treatments 3 months before the intervention - If using sleep aid, the dose needs to be stable for 3 months prior to the enrollment - Ability to use the electronic devices (computer, tablet) and assess the internet - Willing to attend all of the 8 sessions activities Exclusion Criteria: - Type 1 diabetes mellitus - Night shift work - Insulin therapy - Severe hypoglycemia who required hospitalization or emergency department visit in the past 6 months - History of diabetic ketoacidosis in the past 6 months - Medically unstable conditions eg. renal replacement therapy, liver failure, heart failure, active cancer, epilepsy, unstable cerebrovascular disease - Psychosis, uncontrolled depression - Untreated obstructive sleep apnea or STOP-BANG = 5 - Language/communication/hearing/sight disability - Pregnancy or lactation - Care giver of infant - Harmful alcohol/smoking (=15 standard-drink in men and =8 standard-drink in women) |
Country | Name | City | State |
---|---|---|---|
Thailand | Faculty of Medicine Ramathibodi Hospital Mahidol University | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Mahidol University |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Subjective Sleep Quality | Subjective Sleep Quality as assessed by Pittsburgh Sleep Quality Index | 16 weeks | |
Secondary | Metabolic parameters | Fasting glucose and insulin, hemoglobin A1C | 8 weeks | |
Secondary | High sensitivity c-reactive protein | serum sample for Hs-CRP | 8 weeks | |
Secondary | Patient reported outcomes | Questionnaires to assess depressive symptoms, stress, anxiety, daytime sleepiness, and quality of life | 16 weeks | |
Secondary | Objective sleep parameters | Sleep will be obtained using 1-week accelerometer recording | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |